



Dear Colleagues,

MRC SUPREMO – a Phase III randomised trial to assess the role of adjuvant chest wall irradiation in intermediate risk breast cancer after mastectomy.

We are delighted to announce that November was one of the highest recruiting months in 2012 with 34 patients being recruited to the trial. We would like to thank all those who entered patients. A special thank-you to our colleagues at the EORTC who randomised their 300th patient at the Centre Leon Berard, France on the 3rd December. Your efforts have pushed us closer to our target however we are not there yet. Please keep up this good work over the coming months to ensure we reach our target of 1600 patients. Can December be the highest recruiting month so far...?

Opening/Closing Times over Christmas & New Year

Please note that the randomisation line will be closed from 13.00 on Monday 24th December 2012 and will reopen at 9.00 on Thursday 3rd January 2013. Any patients approached during this time can be randomised when lines re-open.

In addition the tissue bank at the Western General Hospital, Edinburgh will be closed from December 20th to Monday 7th January 2013. Details on processing of any cardiac blood samples within this period can be found within the previous correspondence entitled 'Supremo - Newsletter and extension to recruit patients!'

Welcome to our monitor in China

The team would like to welcome Shirley Wong who has recently started monitoring the participating centres in China. Shirley will visit the Chinese Academy of Medical Sciences - Beijing, Sun Yat-sen University Cancer Center - Guangzhou, West China Hospital Sichuan University - Chengdu and Zhejiang Cancer Hospital – Hangzhou. We wish Shirley well in her voyage across China.

Common Queries

We would also like to use this opportunity to highlight some of the common errors we are finding upon receipt of the Case Report Form (CRF) pages:

- CRF page 11 (Version 2 – November 2010)
Q1: Please enter the date of the last definitive surgery here.
Q2: If mastectomy was not the last definitive surgery then please enter the mastectomy date here.
- CRF page 13 (Version 2 - November 2010)
This page should always be completed and returned, even if the patient did not receive neoadjuvant therapy. If neoadjuvant therapy was not received Q1 should be answered 'No' and page signed and dated, all other questions can be left blank.
- CRF page 14 (Version 2 - November 2010)

Q5: Please enter the maximum dimension of the invasive component of the tumour only. Do not enter the whole tumour size (invasive + DCIS). For multi focal tumours only the largest invasive tumour size should be entered on the CRF page (not the sum of all invasive dimensions).

- CRF page 15 (Version 2 - November 2010)
 - Q6: Please indicate the total intended dose of anthracycline given over the whole course of treatment expressed in mg/m². i.e. if intended dose is 90mg/m² for 4 courses then 360mg/m² should be entered.
 - Q7: Please follow the calculation as above however for total dose anthracycline received.

We plan to send out a data request early 2013 therefore please send us any completed missing pages or data queries by end of 2012. This will ensure our data request is as up to date as possible.

Thanks are also due to the research teams at the following centres who have randomised patients to SUPREMO in November ***[patients in November / total patients recruited to date by site]:***

Dr Andrew Hindley, Blackpool Victoria Hospital (2/11)
Dr Charles Lodwell, Charing Cross Hospital (2/25)
Dr Adrian Harnett, Norfolk & Norwich University Hospital (2/35)
Dr M Stenfert-Kroese, Stedendriehoek en Omstreken (2/13)
D Helen Westernberg, Arnhems Radiotherapeutisch Instituut (1/52)
Dr Jackie Clarke, Belfast City Hospital (1/43)
Dr Peter Canney, Beatson Oncology Centre (1/36)
Dr Kathy Rooke, Broomfield Hospital, Chelmsford (1/2)
Dr Sunil Upadhyay, Castle Hill Hospital Hull (1/24)
Dr Marie-Pierre Sunyach, Centre Leon Berard (1/19)
Dr Blanca Farris, Clinico Y Provincial De Barcelona (1/25)
Dr Geraldine Skailes, Furness General Hospital (1/6)
Dr John Hardman, James Cook University Hospital (1/9)
Dr Sri Kumar, Leeds Teaching Hospitals NHS Trust (1/4)
Dr Paul Burt, MCHT Leighton Hospital (1/4)
Dr Nihal Shah, Mount Vernon Cancer Centre (1/28)
Dr David Hwang, North Devon District Hospital (1/2)
Dr Daniela Lee, Queen Elizabeth Hospital Gateshead (1/3)
Dr Richard Welch, Royal Bolton Hospital (1/29)
Dr David Bloomfield, Royal Sussex County Hospital Brighton (1/14)
Dr Apurna Jegannathen, Staffordshire General Hospital (1/6)
Dr Abbas Chittalia, Stepping Hill Hospital, Stockport (1/13)
Dr Mohini Varughese, Taunton and Somerset NHS Foundation Trust (1/17)
Dr Murray Brunt, University Hospital of North Staffordshire (1/24)
Dr Dayle Hacking, UPMC Whitfield Cancer Centre (1/2)
Dr Diana Ritchie, Victoria ACH, Glasgow (1/7)
Dr Tony Branson, Wansbeck Hospital (1/4)
Dr Matthew Hatton, Weston Park Hospital, Sheffield (1/58)
Dr Rajaram Sripadam, Whiston Hospital, St. Helen's (1/10)
Dr Neil Bayman, Wigan Royal Albert Edward Infirmary (1/24)



We would like to thank you for your continued support over 2012 and take this opportunity to wish you a very Merry Christmas and a Happy New Year!

For any queries you may have please contact the trial team at nss.isdsupremo@nhs.net

With kind regards,

Professor Ian Kunkler
Chief Investigator, MRC/EORTC SUPREMO trial